TP53 and cancer: Importantly, the significantly higher pharmacological potency of the novel MDM2 inhibitors Idasanutlin and Milademetan, which are currently being tested in clinical trials, compared to the non-clinical-stage MDM2 inhibitor Nutlin-3a aligns with previous studies in p53 wild-type cancer cells and is apparently due to the 15.8- and 14.7-fold higher binding activity for MDM2 compared to Nutlin-3a [18,19,21,26].